<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7102522\results\search\drugs\results.xml">
  <result pre="41, 44. On the other hand, the patients who received" exact="ribavirin" post="(1), lopinavir (10, see Fig. 4 )- ritonavir (2)"/>
  <result pre="On the other hand, the patients who received ribavirin (1)," exact="lopinavir" post="(10, see Fig. 4 )- ritonavir (2) and a"/>
  <result pre="who received ribavirin (1), lopinavir (10, see Fig. 4 )-" exact="ritonavir" post="(2) and a corticosteroid had lower 21-day acute respiratory"/>
  <result pre="distress syndrome (ARDS) and death rates than those who received" exact="ribavirin" post="and a corticosteroid 54, 55 combination therapy using interferon"/>
  <result pre="corticosteroid alone (uncontrolled study) [56]. The use of the corticosteroid," exact="methylprednisolone" post="(3, Fig. 3) as a therapeutic intervention for SARS"/>
  <result pre="weeks 2-3 of the illness were higher in patients given" exact="hydrocortisone" post="(n = 10) than those given normal saline (n"/>
  <result pre="phase of the illness, suggesting that early use of pulsed" exact="methylprednisolone" post="(3) might prolong viremia. In the case of patients"/>
  <result pre="In the case of patients with MERS, the combination of" exact="ritonavir" post="(2) + interferon α2a or interferon α-2b resulted in"/>
  <result pre="on coronaviruses infections. Retrospective analyses showed that the combination of" exact="ritonavir" post="(2) + interferon β-1a had no significant effect on"/>
  <result pre="on clinical outcome [48]. In another study, the combination of" exact="ribavirin" post="(1), ritonavir (2) + interferon α-2a resolved viremia within"/>
  <result pre="outcome [48]. In another study, the combination of ribavirin (1)," exact="ritonavir" post="(2) + interferon α-2a resolved viremia within 2 days"/>
  <result pre="severe MERS. Patients with severe MERS who were treated with" exact="methylprednisolone" post="(3) with or without antivirals and interferons had no"/>
  <result pre="and dosing regimens. Drugs including interferon α, β, and γ," exact="ribavirin" post="(1) and inhibitors of cyclophilin 60, 61, 62 were"/>
  <result pre="discovered using this approach. The combination therapy of interferon and" exact="ribavirin" post="showed the best result in treating MERS-CoV infection. Also,"/>
  <result pre="coronaviruses, see Table 2[64]. They identified seven compounds (lycorine, emetine," exact="monensin" post="sodium, mycophenolate mofetil, mycophenolic acid, phenazopyridine, and pyrvinium pamoate)"/>
  <result pre="They identified seven compounds (lycorine, emetine, monensin sodium, mycophenolate mofetil," exact="mycophenolic acid," post="phenazopyridine, and pyrvinium pamoate) from HTS screening as broad-spectrum"/>
  <result pre="as high as of their inhibitions, phenazopyridine, pyrvinium pamoate, and" exact="monensin" post="sodium displayed less CC50 values. Further, in vivo studies"/>
  <result pre="CoVs, de Wilde et al identified four drugs such as" exact="chloroquine" post="(7), chlorpromazine (8), loperamide (9) and lopinavir (10) from"/>
  <result pre="Wilde et al identified four drugs such as chloroquine (7)," exact="chlorpromazine" post="(8), loperamide (9) and lopinavir (10) from the screening"/>
  <result pre="al identified four drugs such as chloroquine (7), chlorpromazine (8)," exact="loperamide" post="(9) and lopinavir (10) from the screening of FDA"/>
  <result pre="drugs such as chloroquine (7), chlorpromazine (8), loperamide (9) and" exact="lopinavir" post="(10) from the screening of FDA approved drugs library"/>
  <result pre="[72] and other coronavirus SARS-CoV [73]. The mechanistic study of" exact="chlorpromazine" post="(8) on MERS-CoV indicated that it inhibited the virus"/>
  <result pre="5 and the activities in Table 3 ). Antidiarrheal agent" exact="loperamide" post="(9), or anti-HIV-1 agent lopinavir (10) were able to"/>
  <result pre="Table 3 ). Antidiarrheal agent loperamide (9), or anti-HIV-1 agent" exact="lopinavir" post="(10) were able to inhibit both MERS-and SARS-CoVs infection"/>
  <result pre="linear with the study by de Wilde et al.[79]. Antiparasitics," exact="mefloquine" post="(20), and amodiaquine dihydrochloride (21) or antibacterial, emetine dihydrochloride"/>
  <result pre="study by de Wilde et al.[79]. Antiparasitics, mefloquine (20), and" exact="amodiaquine" post="dihydrochloride (21) or antibacterial, emetine dihydrochloride hydrate (19) in"/>
  <result pre="MERS-CoV and SARS-CoV at the entry stage. The neurotransmitter inhibitor" exact="triflupromazine" post="(33) inhibited both SARS-CoV and MERS-CoV. In addition to"/>
  <result pre="both SARS-CoV and MERS-CoV. In addition to that, other neurotransmitters" exact="fluphenazine" post="(29) and promethazine (30) were reported to inhibit MERS-CoVs"/>
  <result pre="MERS-CoV. In addition to that, other neurotransmitters fluphenazine (29) and" exact="promethazine" post="(30) were reported to inhibit MERS-CoVs protein-mediated cell-cell fusion"/>
  <result pre="20 and 29 μM, respectively [81]. Kinase signaling pathway inhibitors" exact="imatinib" post="mesylate (35) and dasatinib (36) are known inhibitors of"/>
  <result pre="respectively [81]. Kinase signaling pathway inhibitors imatinib mesylate (35) and" exact="dasatinib" post="(36) are known inhibitors of the Abelson murine leukemia"/>
  <result pre="inhibitor 5.46 2.10 The identified DNA synthesis inhibitors (for example," exact="gemcitabine" post="hydrochloride, 23) those were active against at least one"/>
  <result pre="drug used to prevent rejection in organ transplantation. It inhibits" exact="inosine" post="monophosphate dehydrogenase, a key rate-limiting enzyme in the de"/>
  <result pre="enzyme in the de novo purine synthesis pathway which converts" exact="inosine" post="monophosphate to guanosine monophosphate [83]. The active molecule, mycophenolic"/>
  <result pre="converts inosine monophosphate to guanosine monophosphate [83]. The active molecule," exact="mycophenolic acid" post="(46, see for structure Table 4 ), exhibits broad-spectrum"/>
  <result pre="virus (HBV), hepatitis C virus (HCV) and arboviruses [82]. Recently," exact="mycophenolic acid" post="was identified as a potential anti-MERS-CoV drug by a"/>
  <result pre="result as the treatment of MERS-CoV infected common marmosets with" exact="mycophenolic acid" post="had a worse outcome than untreated animals did [84]."/>
  <result pre="(44) and N-ethylmaleimide (45) as well as the immunosuppressive drug," exact="mycophenolic acid" post="(46), were all independently able to inhibit the proteolytic"/>
  <result pre="(45), 6-mercaptopurine (43), 6-thioguanine (44) were more effective inhibitors, while" exact="mycophenolic acid" post="(46) was a less effective inhibitor against the MERS-CoV"/>
  <result pre="by reacting with cysteine residues, suggesting broad-spectrum characteristics [95]. Notably," exact="disulfiram" post="(47) has been reported as an allosteric inhibitor of"/>
  <result pre="combinations of interferon- α or-β with other antivirals such as" exact="ribavirin" post="and/or lopinavir-ritonavir have been used to treat patients with"/>
  <result pre="SARS or MERS. Overall, combination treatments consisting of interferons and" exact="ribavirin" post="did not consistently improve outcomes 47, 48, 49, 136,"/>
  <result pre="the T cell-mediated adaptive immune response [142]. The calcineurin inhibitor" exact="cyclosporine" post="(90, Fig. 13) inhibits a broad range of CoVs"/>
  <result pre="at standard therapeutic dosages limit its clinical application. Trametinib (91)," exact="selumetinib" post="(92), everolimus, rapamycin, dasatinib, and imatinib are examples of"/>
  <result pre="clinical application. Trametinib (91), selumetinib (92), everolimus, rapamycin, dasatinib, and" exact="imatinib" post="are examples of inhibitors of kinase signaling pathways, which"/>
  <result pre="and SARS-CoV S-mediated cell-cell fusion in vitro[148]. Neurotransmitter inhibitors including" exact="chlorpromazine" post="(8), fluphenazine (29), and promethazine (30), were reported to"/>
  <result pre="S-mediated cell-cell fusion in vitro[148]. Neurotransmitter inhibitors including chlorpromazine (8)," exact="fluphenazine" post="(29), and promethazine (30), were reported to inhibit cell-cell"/>
  <result pre="in vitro[148]. Neurotransmitter inhibitors including chlorpromazine (8), fluphenazine (29), and" exact="promethazine" post="(30), were reported to inhibit cell-cell fusion in a"/>
  <result pre="the entry [158]. Subsequently, cholesterol-binding or depleting agents such as" exact="nystatin" post="(104, Fig. 13) or methyl-β-cyclodextrin (MβCD) (105, Fig. 13)"/>
  <result pre="crystallography and functional assays. Examples include the viroporin inhibitor hexamethylene" exact="amiloride" post="(6, Fig. 1), which reduces the ion channel activity"/>
  <result pre="and MERS-CoV viruses. Inosine monophosphate dehydrogenase (IMPDH) inhibitors such as" exact="ribavirin" post="and mycophenolic acid inhibit an important step in de"/>
  <result pre="viruses. Inosine monophosphate dehydrogenase (IMPDH) inhibitors such as ribavirin and" exact="mycophenolic acid" post="inhibit an important step in de novo synthesis of"/>
  <result pre="infections [169] Mizoribine exerts its activity through selective inhibition of" exact="inosine" post="monophosphate synthetase and guanosine monophosphate synthetase, resulting in the"/>
  <result pre="of guanine nucleotide synthesis without incorporation into nucleotides. The chemotherapeutic" exact="gemcitabine" post="has shown in vitro activity against MERS-CoV and SARS-CoV"/>
  <result pre="of two casesAntivir. Ther.202015879124831606 49ShalhoubS.IFN-α2a or IFN-β1a in combination with" exact="ribavirin" post="to treat Middle East respiratory syndrome coronavirus pneumonia: a"/>
  <result pre="of Middle East respiratorysyndromecoronavirus replication in cell cultureAntimicrobAgentsChemother58201448754884 66SavarinoA.Effects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
  <result pre="mechanisms of action, and self-potentiationSemin. Oncol.221995310 78KangH.Synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin against enterovirusesAntivir. Res.124201511026526589 79BrassA.L.The IFITM proteins mediate"/>
  <result pre="action, and self-potentiationSemin. Oncol.221995310 78KangH.Synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="against enterovirusesAntivir. Res.124201511026526589 79BrassA.L.The IFITM proteins mediate cellular resistance"/>
  <result pre="and inhibition by designed antiviral compoundsAntiviral Res.1152015213825554382 92ChengK.W.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
  <result pre="pneumocytes against SARS coronavirus infection in macaquesNat. Med.10200429029314981511 131HartB.J.Interferon-β and" exact="mycophenolic acid" post="are potent inhibitors of Middle East respiratory syndrome coronavirus"/>
  <result pre="a first-in-class broad-spectrum antiviral agentAntiviral Res.11020149410325108173 133FalzaranoD.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat. Med.1920131313131724013700 134CinatlJ.Treatment of"/>
  <result pre="the Middle East respiratory syndromeCurr. Opin. Pulm. Med.20201423324124626235 140HaffizullaJ.Effect of" exact="nitazoxanide" post="in adults and adolescents with acute uncomplicated influenza: a"/>
  <result pre="Infect. Dis.14201460961824852376 141RossignolJ.F.Clinical trial: randomized, double blind, placebo-controlled study of" exact="nitazoxanide" post="monotherapy for the treatment of patients with chronic hepatitis"/>
  <result pre="of the SARS coronavirus envelope protein ion channelPLoS Pathog.52009e1000511 162WilsonL.Hexamethylene" exact="amiloride" post="blocks E protein ion channels and inhibits coronavirus replicationVirology353200629430616815524"/>
  <result pre="and HR2 domainsInt. J. Mol. Sci.192018487 169MorenoC.Efficacy and safety of" exact="simeprevir" post="with PegIFN/ribavirin in naïve or experienced patients infected with"/>
 </snippets>
</snippetsTree>
